First Choice Neurology

aducanumab

Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients

By Jeffrey Gelblum, MD As a practicing neurologist with over 25 years of experience treating Alzheimer’s disease, I strongly oppose the proposed intention of Centers for Medicare & Medicaid Services (CMS) to restrict coverage of anti-amyloid antibody therapy to only those patients who must participate in an approved hospital-based clinical trial (Coverage with Evidence Development, …

Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients Read More »

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s

In recent years, research has shown that tests of cerebrospinal fluid (CSF) can be a valuable tool for the detection of hallmark proteins that are involved in diseases that cause dementia. For example, amyloid and tau proteins build up in Alzheimer’s disease, and their levels can be measured in CSF. These abnormalities contribute to the …

Lumbar Puncture for Cerebrospinal Fluid is a Vital Tool to Assess Amyloid Build Up in Alzheimer’s Read More »

FDA Approves Promising Alzheimer’s Treatment

Leading Florida Neurologists Available to Speak about Biogen Aducanumab Treatment Alzheimer’s patients and their families, as well as the medical community, are celebrating today’s decision by the FDA to approve Biogen’s Aducanumab, a promising infusion treatment for Alzheimer’s patients. Dr. Jeffrey Gelblum, MD, a board-certified neurologist with First Choice Neurology, the nation’s largest neurology practice, …

FDA Approves Promising Alzheimer’s Treatment Read More »

Biogen Seeks FDA Approval for New Alzheimer’s Drug

Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after data from more patients in two discontinued studies showed that the drug improved cognition at high doses. Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language, Biogen said. In March, …

Biogen Seeks FDA Approval for New Alzheimer’s Drug Read More »

Translate »